Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20382781rdf:typepubmed:Citationlld:pubmed
pubmed-article:20382781lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20382781lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:20382781lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:20382781lifeskim:mentionsumls-concept:C1510802lld:lifeskim
pubmed-article:20382781lifeskim:mentionsumls-concept:C1545588lld:lifeskim
pubmed-article:20382781lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:20382781lifeskim:mentionsumls-concept:C0034390lld:lifeskim
pubmed-article:20382781pubmed:issue2lld:pubmed
pubmed-article:20382781pubmed:dateCreated2010-4-12lld:pubmed
pubmed-article:20382781pubmed:abstractTextThe purpose of this study was to assess adherence to vascular protection drugs in diabetic patients using a cohort of diabetic patients aged >or=30 years, covered by the public drug insurance in the province of Quebec, excluding gestational diabetes and patients who were hopitalized or died during the 1-year follow-up. Drug adherence was measured using the medication possession ratio. Multivariate analyses, including logit and multinomial logit were used. Of the 170,381 diabetics (mean age: 62 +/- 14 years), 18% and 32% were regular users of ASA and ACEIs/ARBs, respectively. Regular use increased with age (p<0.0001) and comorbidities (p<0.0001). Rural inhabitants were more likely to use ACEIs/ARBs (OR: 1.29; 95% CI: 1.26-1.32) and to be regular users (OR: 1.36; 95% CI: 1.32-1.39). Similar results were found for ASA. In conclusion, despite the high cardiovascular risks associated with diabetes, less than one-third of diabetic adults took vascular-protection drugs regularly. This important issue needs proper attention.lld:pubmed
pubmed-article:20382781pubmed:languageenglld:pubmed
pubmed-article:20382781pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382781pubmed:citationSubsetIMlld:pubmed
pubmed-article:20382781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20382781pubmed:statusMEDLINElld:pubmed
pubmed-article:20382781pubmed:monthAprlld:pubmed
pubmed-article:20382781pubmed:issn1752-8984lld:pubmed
pubmed-article:20382781pubmed:authorpubmed-author:GrégoireJean-...lld:pubmed
pubmed-article:20382781pubmed:authorpubmed-author:PâquetMariane...lld:pubmed
pubmed-article:20382781pubmed:authorpubmed-author:VanasseAlainAlld:pubmed
pubmed-article:20382781pubmed:authorpubmed-author:CourteauJosia...lld:pubmed
pubmed-article:20382781pubmed:authorpubmed-author:CarpentierAnd...lld:pubmed
pubmed-article:20382781pubmed:authorpubmed-author:AsghariShabna...lld:pubmed
pubmed-article:20382781pubmed:authorpubmed-author:DrouinCatheri...lld:pubmed
pubmed-article:20382781pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20382781pubmed:volume7lld:pubmed
pubmed-article:20382781pubmed:ownerNLMlld:pubmed
pubmed-article:20382781pubmed:authorsCompleteYlld:pubmed
pubmed-article:20382781pubmed:pagination167-71lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:meshHeadingpubmed-meshheading:20382781...lld:pubmed
pubmed-article:20382781pubmed:year2010lld:pubmed
pubmed-article:20382781pubmed:articleTitleAdherence to vascular protection drugs in diabetic patients in Quebec: a population-based analysis.lld:pubmed
pubmed-article:20382781pubmed:affiliationPRIMUS Group, Centre de recherche clinique Etienne-Le Bel, CHUS, Sherbrooke (QC), Canada.lld:pubmed
pubmed-article:20382781pubmed:publicationTypeJournal Articlelld:pubmed